Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer

NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group
(NYSE: SCR), a leading manufacturer and supplier of branded generic and
innovative anti-cancer pharmaceuticals in China, announced today the
appointment of Dr. Peng Wang as Chief Scientific Officer.
Dr. Wang will lead the company's R&D team in developing new products and
innovative research projects. He will also participate in the strategic
planning of the R&D department and manage domestic and international research
collaborations.
Dr. Wang has two decades of experience in pharmaceutical R&D, most
recently serving as Vice President of Discovery Biology at WuXi PharmaTech.
Previously, Dr. Wang was a Research Fellow at Schering-Plough Research
Institute where he worked for eighteen years with increasing responsibilities.
Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo in
1990.
"As a recognized biopharmaceutical expert, Dr. Wang is well positioned to
contribute to Simcere's strategic development in this area," commented Mr.
Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical
Group, "Simcere is committed to investing in research and development to
support our long term growth, and we are delighted that Dr. Wang has agreed to
join us."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading manufacturer
and supplier of branded generic and innovative pharmaceuticals in China. In
recent years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics, and has introduced an
innovative anti-cancer medication Endu, a first-to-market medication Sinofuan,
and first-to-market generics such as Bicun and Anxin. Simcere manufactures and
sells antibiotics, anti-cancer medication and stroke management medication.
Simcere concentrates its research and development efforts on the treatment of
diseases with high incidence and/or mortality rates and for which there is a
clear demand for more effective pharmacotherapy such as cancer, strokes,
orthopaedics and infectious diseases. For more information about Simcere
Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group

For investor and media inquiries, please contact: ir@simcere.com; Or In
Nanjing: Frank Zhigang Zhao, Chief Financial Officer of Simcere Pharmaceutical
Group, +86-25-8556-6666 x8818; Or In Beijing: Kejia Wu of Brunswick Group,
+86-10-6566-2256; In Hong Kong: Joseph Lo Chi-Lun of Brunswick Group,
+852-3512-5000; Or In New York: Kate Tellier of Brunswick Group LLC,
+1-212-333-3810